-
Rituximab, sold
under the
brand name
Rituxan among others, is a
monoclonal antibody medication used to
treat certain autoimmune diseases and
types of...
- 90% to less than 20%. Immunosuppressants, such as glucocorticoids, and
rituximab may also be used.
Platelet transfusions are
generally not recommended...
- as
rituximab or
cyclophosphamide and high-dose
corticosteroids to
control the
symptoms of the disease, and azathioprine, methotrexate, or
rituximab to...
- of t-FL (e.g., the
addition to
standard chemotherapy of
agents such as
rituximab) have
improved overall survival times.
These newer regimens may also delay...
-
positive for the B cell
marker CD20. The anti-CD20
monoclonal antibody Rituximab has been used in
lymphocyte predominant Hodgkin lymphoma with encouraging...
-
destruction by the
immune system.
Examples of such
antibodies include rituximab (targeting CD-20),
trastuzumab (targeting HER-2), and
cetuximab (targeting...
- corticosteroids.
Sometimes the
chimeric anti-CD20
monoclonal antibody,
rituximab, is
added to this
treatment regimen to form the R-CHOP regimen. R-miniCHOP...
- such as
rituximab,
which are
increasingly being used as first-line treatment. In the
summer of 2018, the FDA
granted full
approval to
rituximab for this...
-
monoclonal antibody drug that
targets the disease's
cancerous B-cells,
usually rituximab.
Through these treatments, more than half of all
patients with
DLBCL can...
- It is
often combined with
rituximab. In this case it is
called R-EPOCH or EPOCH-R. The R-EPOCH
regimen consists of:
Rituximab: an anti-CD20 monoclonal...
